Skip page top navigationFDA Logo--links to FDA home page Logo of and Link to start page of Office of Regulatory Affairs, U.S. Food and Drug Administration U.S. Food and Drug Administration Office of Regulatory Affairs HHS Logo and link to Department of Health and Human Services website

FDA Home Page | Federal-State | Import Program | Compliance | Inspection | Science | ORA Search

Sec. 254.100 Source Plasma [] - Use of Units from Donors Subsequently Found to be Reactive to a Serologic Test for Syphilis (CPG 7134.15)

BACKGROUND:

There has been some concern and confusion relating to the use of units of Source Plasma * * collected from donors who are subsequently found to be reactive to a serologic test for syphilis (STS). The initial and four-month STS is designed primarily to identify the disease in donors and to promote treatment of affected donors; therefore, the donor, once identified as STS reactive, may not obe plasmapheresed again until his/her serologic test is nonreactive or collection is performed under the provisions of 21 CFR 640.65(b)(2)(iii) and (iv). These provisions permit, under certain conditions, plasmapheresis of donors with biologic-false-positive reactions; or those with positive results. However, units collected from donors prior to their being identified as STS reactive may be issued as Source Plasma, [] since the disease-causing spirochetes are destroyed during the storage and/or fractionation of the plasma.

POLICY:

Units of plasma collected from plasmapheresis donors who were not known to be reactive to a STS prior to the plasmapheresis procedure may be shipped as Source Plasma []. These units need not be labeled or identified in shipping records as STS reactive, since such requirements pertain only to units collected from donors known to be STS reactive.

*Material between asterisks is new or revised*

[] Indicates material has been deleted

Issued: 3/14/80 as 7134.11
Revised: 10/1/80, 2/1/84, 3/95